CCR7 and cancer: These results confirm that CD8+ T-lymphocytes, when treated with MEKi and nivolumab in vitro, become T-cells, having high stable CCR7 expression and being resistant to the cytotoxic effect of cancer cells and distinct from naive T-lymphocytes.